Home›Research›Compare›CJC-1295 (without DAC) vs MK-677
Peptide ComparisonCJC-1295 (without DAC) vs MK-677
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC-1295
Half-life: ~30 minutes
446 providers listed
MK-677
Ibutamoren
Half-life: 24 hours
64 providers listed
MK-677 carries stronger published evidence (RCT, 2 key studies) than CJC-1295 (without DAC) (Review, 1); both are research compounds.
CJC-1295 (without DAC)
Evidence
Half-life
~30 minutes
MK-677
Evidence
Half-life
24 hours
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | MK-677 |
| Less frequent dosing (longer half-life) | MK-677 |
| Oral administration option | MK-677 |
| Lower typical price per mg | MK-677 |
| More provider options (446 vs 64) | CJC-1295 (without DAC) |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
MK-677
CJC-1295 (without DAC)
MK-677
Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients:…
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secr…
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About MK-677
MK-677 mimics the action of ghrelin by binding to and activating the GHSR-1a receptor in the pituitary gland, stimulating pulsatile GH release. Its oral bioavailability distinguishes it from peptide-based GH secretagogues and its prolonged half-life results in sustained IGF-1 elevation. Research protocols have explored its effects on lean body mass, bone mineral density, and sleep architecture.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceMK-677
Class-based (investigational)
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
CJC-1295 (without DAC)
MK-677
Where to source these peptides
CJC-1295 (without DAC)
446 listed
Browse directory →
Providers offeringMK-677
64 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs MK-677 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/mk-677